Vivo Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Vivo Capital’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-139	Closed	-$35K	–	53
2022 Q1	$35K	Hold	139	–	–	﹤0.01%	54
2021 Q4	$22K	Sell	139 -15,514	-99%	-$3M	﹤0.01%	55
2021 Q3	$3.14M	Sell	15,653 -44,056	-74%	-$10.5M	0.14%	54
2021 Q2	$15.3M	Hold	59,709	–	–	0.66%	30
2021 Q1	$15.9M	Hold	59,709	–	–	0.56%	36
2020 Q4	$22M	Hold	59,709	–	–	0.98%	24
2020 Q3	$14.6M	Hold	59,709	–	–	0.84%	35
2020 Q2	$17.2M	Hold	59,709	–	–	1.23%	22
2020 Q1	$12.2M	Buy	+59,709	New	+$19M	1.1%	25
2019 Q3	–	Sell	-59,709	Closed	-$19M	–	32
2019 Q2	$19M	Hold	59,709	–	–	1.78%	17
2019 Q1	$25M	Hold	59,709	–	–	2.5%	14
2018 Q4	$18.2M	Hold	59,709	–	–	2.32%	12
2018 Q3	$21.5M	Hold	59,709	–	–	2.17%	16
2018 Q2	$21.9M	Hold	59,709	–	–	2.82%	12
2018 Q1	$17.6M	Hold	59,709	–	–	2.5%	11
2017 Q4	$25M	Buy	59,709 +139	+0.2%	+$49.7K	5.35%	6
2017 Q3	$19.7M	Hold	59,570	–	–	3.97%	10
2017 Q2	$14.1M	Hold	59,570	–	–	3.56%	9
2017 Q1	$20.5M	Hold	59,570	–	–	6.02%	5
2016 Q4	$20.8M	Hold	59,570	–	–	6.86%	5
2016 Q3	$23.9M	Buy	59,570 +6,250	+12%	+$3.19M	7.46%	3
2016 Q2	$31.7M	Hold	53,320	–	–	8.66%	3
2016 Q1	$26.8M	Buy	+53,320	New	+$26.5M	6.73%	5

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vivo Capital's EIGR Position: Q2 2022 in Review

Vivo Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2022, closing a stake of 139 shares — an estimated $35K sold.

Vivo Capital first reported a position in EIGR in Q1 2016 and held it in 23 quarters. The position peaked at $31.7M in Q2 2016. 91 funds tracked by Wall St. Rank hold EIGR as of Q2 2022.

Vivo Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
Vivo Capital sold 139 Eiger BioPharmaceuticals, Inc. shares in Q2 2022, an estimated $35K.
Vivo Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2016 and held it in 23 quarters.
Vivo Capital's Eiger BioPharmaceuticals, Inc. position peaked at $31.7M in Q2 2016.
91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2022.

Based on Vivo Capital's 13F filing for Q2 2022, filed 15 Aug 2022.